DURECT Corp (DRRX.OQ)
DRRX.OQ on NASDAQ Stock Exchange Global Market
1.07USD
21 Sep 2018
1.07USD
21 Sep 2018
Change (% chg)
$-0.03 (-2.73%)
$-0.03 (-2.73%)
Prev Close
$1.10
$1.10
Open
$1.08
$1.08
Day's High
$1.09
$1.09
Day's Low
$1.03
$1.03
Volume
543,153
543,153
Avg. Vol
143,883
143,883
52-wk High
$2.55
$2.55
52-wk Low
$0.75
$0.75
About
Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY... (more)
Overall
| Beta: | 0.84 |
| Market Cap(Mil.): | $173.34 |
| Shares Outstanding(Mil.): | 162.00 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| DRRX.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 108.33 | 32.69 |
| EPS (TTM): | -0.00 | -- | -- |
| ROI: | -2.92 | 1.50 | 12.72 |
| ROE: | -7.28 | 0.19 | 14.85 |
BRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz
* DURECT ANNOUNCES AMENDMENT TO LICENSING AGREEMENT WITH SANDOZ RELATED TO POSIMIR® (SABER®-BUPIVACAINE)
BRIEF-Durect Corporation Q1 Loss Per Share $0.05
* DURECT CORPORATION ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Competitors
| Price | Chg | |
|---|---|---|
| Hisamitsu Pharmaceutical Co Inc (4530.T) | ¥8,650 | +70.00 |
| Johnson & Johnson (JNJ.N) | $142.88 | +0.90 |
| Pfizer Inc. (PFE.N) | $44.06 | +0.31 |
| Novartis AG (NOVN.S) | CHF81.88 | -- |
| AstraZeneca plc (AZN.L) | 5,670.00 | -- |
| Eli Lilly And Co (LLY.N) | $106.33 | +0.26 |
| Kimberly Clark Corp (KMB.N) | $116.72 | -0.05 |
| Bristol-Myers Squibb Co (BMY.N) | $62.25 | +0.50 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,034.45 | -- |
| Covidien Ltd (COV.N) | -- | -- |
Estimates